Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2018 2
2019 1
2021 2
2022 2
2023 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F. Bordet C, et al. Psychopharmacology (Berl). 2023 Jan;240(1):199-202. doi: 10.1007/s00213-022-06293-4. Epub 2022 Dec 14. Psychopharmacology (Berl). 2023. PMID: 36515735
CONCLUSIONS: This large study in a real-world setting suggests that sertindole and ziprasidone were the antipsychotics drugs associated with the highest risk of QT prolongation reporting. Our results suggest that lurasidone is less associated with QT interval prolon …
CONCLUSIONS: This large study in a real-world setting suggests that sertindole and ziprasidone were the antipsychotics drugs associated with …
An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use.
Melo L, Pillai A, Kompella R, Patail H, Aronow WS. Melo L, et al. Expert Opin Drug Saf. 2024 Sep;23(9):1127-1134. doi: 10.1080/14740338.2024.2392002. Epub 2024 Aug 13. Expert Opin Drug Saf. 2024. PMID: 39126643 Review.
INTRODUCTION: The rising prevalence of psychiatric disorders has resulted in a significant increase in the use of antipsychotic medications. These agents may prolong the corrected QT interval (QTc), running the risk of precipitating ventricular arrhythmias, notably Tors …
INTRODUCTION: The rising prevalence of psychiatric disorders has resulted in a significant increase in the use of antipsychotic medications. …
Brexpiprazole: A Review in Schizophrenia.
Frampton JE. Frampton JE. Drugs. 2019 Feb;79(2):189-200. doi: 10.1007/s40265-019-1052-5. Drugs. 2019. PMID: 30671869 Review.
Brexpiprazole (Rxulti( ), Rexulti( )) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in some other countries, including Japan. ...Brexpiprazole was generally well tolerated, e …
Brexpiprazole (Rxulti( ), Rexulti( )) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU ( …
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L. Citrome L. Int J Clin Pract. 2015 Sep;69(9):978-97. doi: 10.1111/ijcp.12714. Epub 2015 Aug 6. Int J Clin Pract. 2015. PMID: 26250067
When the results for brexpiprazole 1, 2 and 3 mg from the two Phase III MDD trials are pooled together, 23.2% of the patients receiving brexpiprazole were responders, vs. 14.5% for placebo, yielding a NNT of 12 (95% CI 8-26). Brexpiprazole was well tolerated …
When the results for brexpiprazole 1, 2 and 3 mg from the two Phase III MDD trials are pooled together, 23.2% of the patients receivi …
Cariprazine: A new partial dopamine agonist with a familiar profile.
Hope J, Keks NA. Hope J, et al. Australas Psychiatry. 2022 Jun;30(3):382-385. doi: 10.1177/10398562211064254. Epub 2022 Feb 13. Australas Psychiatry. 2022. PMID: 35156402
Cariprazine causes more akathisia than aripiprazole or brexpiprazole but is less prone to insomnia, weight gain and sedation. Risks for hyperprolactinaemia and QT(c) prolongation are low. ...
Cariprazine causes more akathisia than aripiprazole or brexpiprazole but is less prone to insomnia, weight gain and sedation. Risks f …
Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.
Aronow WS, Shamliyan TA. Aronow WS, et al. Ann Transl Med. 2018 Apr;6(8):147. doi: 10.21037/atm.2018.03.17. Ann Transl Med. 2018. PMID: 29862236 Free PMC article.
Our search in PubMed, EMBASE, the Cochrane Library, clinicaltrials.gov, and PharmaPendium up to October 2017 identified studies that examined aripiprazole, quetiapine, risperidone, olanzapine, ziprasidone and brexpiprazole. RESULTS: Low quality evidence suggests that aripi …
Our search in PubMed, EMBASE, the Cochrane Library, clinicaltrials.gov, and PharmaPendium up to October 2017 identified studies that examine …
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. Forbes A, et al. Int J Neuropsychopharmacol. 2018 May 1;21(5):433-441. doi: 10.1093/ijnp/pyy002. Int J Neuropsychopharmacol. 2018. PMID: 29415258 Free PMC article. Clinical Trial.
BACKGROUND: Brexpiprazole is a serotonin-dopamine activity modulator with efficacy in acute schizophrenia and relapse prevention. ...CONCLUSIONS: Treatment with brexpiprazole 1-4 mg/d was generally well tolerated for up to 52 weeks in patients with schizophrenia. .. …
BACKGROUND: Brexpiprazole is a serotonin-dopamine activity modulator with efficacy in acute schizophrenia and relapse prevention. ... …
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
Citrome L. Citrome L. CNS Drugs. 2013 Nov;27(11):879-911. doi: 10.1007/s40263-013-0105-7. CNS Drugs. 2013. PMID: 24062193
Using the framework and philosophy of EBM, this systematic review summarizes the pharmacology, efficacy, and tolerability of newly approved oral antipsychotics, including iloperidone, asenapine, and lurasidone, and outlines what is known about agents that are in late-stage clinic …
Using the framework and philosophy of EBM, this systematic review summarizes the pharmacology, efficacy, and tolerability of newly approved …
Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval.
Okayasu H, Shinozaki T, Takano Y, Sugawara N, Fujii K, Yasui-Furukori N, Ozeki Y, Shimoda K. Okayasu H, et al. Neuropsychiatr Dis Treat. 2021 Jan 27;17:239-249. doi: 10.2147/NDT.S287042. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 33542628 Free PMC article.
Recently, improved methods, namely, QT dispersion (QTD), QTD ratio (QTDR), T wave peak-to-end interval (Tp-e), Tp-e/QT ratio and Tp-e/QTc ratio, have been regarded as proarrhythmic risk markers. ...Levomepromazine, quetiapine, asenapine, clozapine and carbamazepine …
Recently, improved methods, namely, QT dispersion (QTD), QTD ratio (QTDR), T wave peak-to-end interval (Tp-e), Tp-e/QT ratio a …
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study.
Ishigooka J, Inada K, Niidome K, Aoki K, Kojima Y, Iwashita S, Yamada S. Ishigooka J, et al. Hum Psychopharmacol. 2021 Jul;36(4):e2777. doi: 10.1002/hup.2777. Epub 2021 Jan 26. Hum Psychopharmacol. 2021. PMID: 33496984 Free PMC article.
OBJECTIVES: To determine the long-term safety of switching to brexpiprazole from aripiprazole or non-aripiprazole dopamine antagonists. METHODS: Post-hoc analysis of 56-week study of Japanese outpatients with schizophrenia switched to brexpiprazole 2 mg/day over 4-w …
OBJECTIVES: To determine the long-term safety of switching to brexpiprazole from aripiprazole or non-aripiprazole dopamine antagonist …